Loading the company…
Loading the company…
㈜에스케이바이오텍
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Daejeon, founded in 2015. Industry: Bio & Pharma. Revenue for 2025 was ₩216.0bn. It has 812 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2012-11-08 · latest registration 2018-04-03 · newest first
본 발명은 4-아세톡시아세토페논을 출발물질로 4-아세톡시페닐메틸카르비놀을 경유하여 4-아세톡시스티렌을 제조하는 방법에 관한 것으로, 보다 상세하게는 무기 산화물 담체에 금속이 담지된 촉매를 사용한 연속적 수소화 반응공정에 의하여 4-아세톡시아세토페논으로부터 4-아세톡시페닐메틸 카르비놀으로 제조하고, 이를 고체산 촉매를 이용한 연속 탈수반응에 의하여 4-아세톡시스티렌으로 제조하는 방법에 관한 것이다.
본 발명은 광학적으로 순수한 (S)-페닐아미노산 유도체를 담지된 금속 담지 촉매 하에서 연속적으로 수소화하여 광학적으로 순수한 (S)-사이클로헥실아미노산 유도체를 제조하는 방법을 개시한다. 본 발명은 (S)-사이클로헥실아미노산 유도체를 고수율, 고순도로 제조할 수 있는 친환경적이면서도 경제적인 방법이다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 207.0 | 216.0 |
| Cost of sales | 129.7 | 128.5 |
| Gross profit (loss) | 77.3 | 87.5 |
| Selling, general and administrative expenses | 38.2 | 48.4 |
| Operating income (loss) | 39.2 | 39.1 |
| Non-operating income | 14.4 | 16.5 |
| Other gains | 0.7 | 1.0 |
| Finance income | 13.7 | 15.5 |
| Non-operating expenses | 11.3 | 16.8 |
| Other losses | 0.2 | 0.1 |
| Finance costs | 11.1 | 16.7 |
| Profit (loss) before tax | 42.2 | 38.8 |
| Income tax expense | 8.8 | 6.8 |
| Net income (loss) | 33.4 | 32.0 |
Revenue ₩216bn, up 4.3% YoY.
Operating margin 18.1% (prior 18.9%).
Net income ₩32bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-05